Healthcare (Public Health) in United States

passed · United States · House Jul 21, 2026

HR 4348: To reauthorize the Kay Hagan Tick Act, and for other purposes.

This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.

Topics ✓ Healthcare

Sub-Topics Public Health

in committee · United States · House Jun 26, 2025

HR 4165: To amend the Public Health Service Act to provide for the inclusion of a biological attribution strategy, and an early warning strategy and implementation plan, in the National Health Security Strategy, and for other purposes.

This bill requires federal health agencies to develop two new strategies within the National Health Security Strategy. First, a "biological attribution strategy" to clarify which agencies handle identifying the source of biological threats (like disease outbreaks) and how they coordinate, including using new technologies for detection. Second, an "early warning strategy" focused on rapidly spotting emerging health threats (biological, chemical, or radiological) through tools like wastewater testing and airport screenings, while avoiding duplicated efforts. It mandates coordination with state health departments, private labs, and intelligence agencies to streamline response capabilities. The bill directly affects federal agencies (like CDC and National Intelligence) and their coordination with state/local partners, without creating new funding or altering existing laws.

Topics ✓ Healthcare ✓ Technology

Sub-Topics Public Health

in committee · United States · House Feb 26, 2025

HR 1632: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

HR 1632, the *Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025*, would allow the FDA to grant "reciprocal marketing approval" for drugs, biological products, and medical devices already approved in specific countries (like those listed in section 802(b)(1) or the UK). This would let manufacturers market these products in the U.S. without going through a full U.S. approval process, provided they meet safety and effectiveness criteria and address unmet medical needs. The FDA must make a decision within 30 days of a request, and Congress could override denials using a joint resolution. This directly affects drug/device manufacturers seeking faster U.S. market access for foreign-approved treatments.

Topics ✓ Healthcare

Sub-Topics Public Health

in committee · United States · House Sep 30, 2025

HR 5630: To amend the Public Health Service Act to require additional information in State plans for Substance Use Prevention, Treatment, and Recovery Services block grants.

HR 5630 amends the Public Health Service Act to require states receiving Substance Use Prevention, Treatment, and Recovery Services block grants to include specific new information in their state plans. The bill mandates that states describe four key elements: the types of drugs used in medication-assisted treatment (MAT) within their system, their protocols to prevent MAT diversion or misuse, data on misuse (including mixing MAT drugs with other prescriptions), and their drug screening protocols for MAT patients. These requirements apply directly to states administering the block grant programs. The change focuses on improving transparency and data collection around MAT services without altering existing grant funding or treatment protocols.

Topics ✓ Healthcare

Sub-Topics Public Health Substance Abuse

in committee · United States · House Sep 18, 2025

HR 5488: Special Diabetes Program for Indians Reauthorization Act of 2025

This bill reauthorizes the Special Diabetes Program for Indians (SDPI) through fiscal year 2030, extending annual funding of $160 million per year. It directly affects American Indian and Alaska Native communities, which face significantly higher rates of diabetes, by ensuring continued federal support for diabetes prevention and treatment programs. The key provision amends the Public Health Service Act to add $160 million in annual funding for fiscal years 2026 through 2030, with funds remaining available until expended. This reauthorization maintains existing program funding levels without altering eligibility or program structure.

Topics ✓ Budget & Taxes ✓ Healthcare

Sub-Topics Public Health Tags Tribal Nations

in committee · United States · Senate Dec 17, 2025

S 3529: Public Health Air Quality Act of 2025

The Public Health Air Quality Act of 2025 requires the Environmental Protection Agency to implement comprehensive monitoring of hazardous air pollutants at specific facilities posing the greatest health risks. It mandates fenceline monitoring for pollutants like benzene, formaldehyde, and ethylene oxide at facilities in census tracts with elevated cancer risks or other health impacts, and requires deployment of 80 additional air quality monitoring stations in communities disproportionately affected by pollution. The EPA must publish all monitoring data publicly within 7 days of collection in accessible formats and multiple languages, with data maintained for at least 10 years. The bill allocates $146 million for implementation in fiscal years 2026-2027 to support this monitoring network.

Topics ✓ Environment ✓ Healthcare

Sub-Topics Air Quality Environmental Justice Public Health

in committee · United States · House Jan 8, 2026

HR 6977: Better Care for PFAS Patients Act of 2026

This bill requires the Agency for Toxic Substances and Disease Registry (ATSDR) to partner with the National Academies to assess the health effects of per- and polyfluoroalkyl substances (PFAS) found in human tissues and develop clinical recommendations for addressing them. It mandates that this assessment be completed within 2 years of the law's enactment, updated every 5 years, and includes input from PFAS-exposed communities. Based on these assessments, ATSDR must issue and regularly update public clinical guidance for healthcare providers and public health authorities on managing PFAS health effects. The guidance must be posted online and shared with state/local health officials and medical professionals within 5 years of the agreement and every 5 years thereafter.

Topics ✓ Environment ✓ Healthcare

Sub-Topics Drinking Water Hazardous Materials Public Health

in committee · United States · House Jul 16, 2025

HR 4473: BIRD Health Act of 2025

HR 4473, the BIRD Health Act of 2025, establishes a new U.S.-Israel bilateral program to fund joint research and development of health technologies. It directly affects U.S. and Israeli health institutions, companies, and academic organizations by providing $10 million annually (2026-2032) for collaborative projects in medical devices, telemedicine, diagnostics, pharmaceuticals, genomics, and infectious disease prevention. Key provisions include funding for R&D, commercialization support, health system strengthening, and joint manufacturing of biological products, with projects selected based on innovation, commercial potential, and partnership strength. The program will be administered by the existing BIRD Foundation under U.S. Health and Human Services oversight, aiming to accelerate health technology development and deployment through U.S.-Israel collaboration.

Topics ✓ Healthcare ✓ Technology

Sub-Topics Public Health Telehealth

in committee · United States · House Sep 30, 2025

HR 5629: To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.

HR 5629 would prevent the Department of Health and Human Services' final rule on opioid treatment medications from taking effect, except for changes to accreditation standards for opioid treatment programs. The rule, published in February 2024, aimed to expand access to certain medications for opioid use disorder by modifying treatment protocols. This bill would maintain current regulations for medication-assisted treatment by blocking the rule's implementation, while leaving accreditation requirements unchanged. As a result, existing treatment guidelines would remain in place, but program accreditation standards would still be updated per the rule's exception.

Topics ✗ Healthcare

Sub-Topics Public Health Substance Abuse Telehealth

in committee · United States · House Sep 4, 2025

HR 5126: HIV Prevention Now Act

HR 5126, the HIV Prevention Now Act, appropriates $2.165 billion for the CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention for fiscal year 2026. This funding is in addition to existing CDC appropriations and must be used exclusively by that specific center for its programs, with no transfer to other entities. The bill directly affects the CDC's public health operations by providing dedicated resources for prevention and treatment programs targeting HIV, viral hepatitis, STDs, and tuberculosis. It does not create new policies or alter eligibility but ensures sustained funding for existing prevention efforts at the federal level.

Topics ✓ Budget & Taxes ✓ Healthcare

Sub-Topics Appropriations Public Health

All healthcare bills